Literature DB >> 11235996

Expression of CD44 in effusions of patients diagnosed with serous ovarian carcinoma--diagnostic and prognostic implications.

H S Berner1, B Davidson, A Berner, B Risberg, G B Kristensen, C G Trope, G Van de Putte, J M Nesland.   

Abstract

CD44 is a family of cell adhesion molecules involved in a variety of cellular functions. The present study analysed the expression of two CD44 isoforms in serous effusions of patients diagnosed with ovarian carcinoma and corresponding primary and metastatic lesions. Fifty-eight effusions, 23 primary ovarian tumours, and 44 metastatic lesions were studied for protein expression of CD44s and v3-10 using immunohistochemistry. Results were correlated with clinical parameters. CD44v3-10 was seen in carcinoma cells in the majority of cases at all sites. Malignant effusions showed an up-regulation of CD44s compared to both primary tumours and metastatic solid lesions. Mesothelial cells frequently expressed CD44s, but were rarely immunoreactive for v3-10. CD44s immunoreactivity in cancer cells in effusions was significantly more often observed in patients with FIGO stage 3 than in stage 4 patients (P = 0.045). Staining results did not correlate with age, effusion site, metastatic site, tumour grade or residual tumour mass after initial surgery. Likewise, comparison of overall and disease-free survival with expression of the CD44 isoforms studied did not reveal any statistically significant associations. The up-regulation in CD44 levels in effusions, primarily in stage 3 disease, suggests that adhesion of ovarian carcinoma cells to mesothelium may be regulated at the level of CD44s expression, and provides further evidence of phenotypic alteration in the transition from primary tumour cell clones to effusions. The similar expression profile of CD44 in carcinoma cells in peritoneal and pleural effusions supports our previous observations and the hypothesis that carcinoma cells in peritoneal effusions are truly metastatic.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11235996     DOI: 10.1023/a:1006711320107

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  35 in total

1.  Hyaluronate binding probe and CD44 in the differential diagnosis of malignant effusions: disappointing results in cytology material.

Authors:  A C Filie; A Abati; P Fetsch; N Azumi
Journal:  Diagn Cytopathol       Date:  1998-06       Impact factor: 1.582

2.  Expression of CD44 and variant isoforms in cervical intraepithelial neoplasia.

Authors:  A Dellas; E Schultheiss; A C Almendral; J Torhost; F Gudat
Journal:  Gynecol Oncol       Date:  1996-08       Impact factor: 5.482

3.  In vivo inhibition of CD44 limits intra-abdominal spread of a human ovarian cancer xenograft in nude mice: a novel role for CD44 in the process of peritoneal implantation.

Authors:  T Strobel; L Swanson; S A Cannistra
Journal:  Cancer Res       Date:  1997-04-01       Impact factor: 12.701

4.  Expression of the hyaluronan receptor, CD44S, in epithelial ovarian cancer is an independent predictor of survival.

Authors:  S Kayastha; A N Freedman; M S Piver; J Mukkamalla; M Romero-Guittierez; B A Werness
Journal:  Clin Cancer Res       Date:  1999-05       Impact factor: 12.531

5.  E-cadherin and alpha-, beta-, and gamma-catenin protein expression is up-regulated in ovarian carcinoma cells in serous effusions.

Authors:  B Davidson; A Berner; J M Nesland; B Risberg; H S Berner; C G Tropè; G B Kristensen; M Bryne; V Ann Florenes
Journal:  J Pathol       Date:  2000-12       Impact factor: 7.996

6.  Prognostic value of CD44 splice variant expression in ovarian cancer.

Authors:  M Uhl-Steidl; E Müller-Holzner; A G Zeimet; G R Adolf; G Daxenbichler; C Marth; O Dapunt
Journal:  Oncology       Date:  1995 Sep-Oct       Impact factor: 2.935

7.  Binding of ovarian cancer cells to peritoneal mesothelium in vitro is partly mediated by CD44H.

Authors:  S A Cannistra; G S Kansas; J Niloff; B DeFranzo; Y Kim; C Ottensmeier
Journal:  Cancer Res       Date:  1993-08-15       Impact factor: 12.701

8.  Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons.

Authors:  G R Screaton; M V Bell; D G Jackson; F B Cornelis; U Gerth; J I Bell
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-15       Impact factor: 11.205

9.  In vitro degradation of extracellular matrix by human ovarian carcinoma cells.

Authors:  M J Niedbala; K Crickard; R J Bernacki
Journal:  Clin Exp Metastasis       Date:  1987 Apr-Jun       Impact factor: 5.150

10.  Migration of human melanoma cells on hyaluronate is related to CD44 expression.

Authors:  L Thomas; T Etoh; I Stamenkovic; M C Mihm; H R Byers
Journal:  J Invest Dermatol       Date:  1993-02       Impact factor: 8.551

View more
  14 in total

1.  HMGA2 protein expression in ovarian serous carcinoma effusions, primary tumors, and solid metastases.

Authors:  Thea Eline Hetland; Arild Holth; Janne Kærn; Vivi Ann Flørenes; Claes G Tropé; Ben Davidson
Journal:  Virchows Arch       Date:  2012-04-04       Impact factor: 4.064

2.  EMMPRIN (extracellular matrix metalloproteinase inducer) is a novel marker of poor outcome in serous ovarian carcinoma.

Authors:  Ben Davidson; Iris Goldberg; Aasmund Berner; Gunnar B Kristensen; Reuven Reich
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

3.  Expression of the 67 kDa laminin receptor and the alpha6 integrin subunit in serous ovarian carcinoma.

Authors:  Vered Givant-Horwitz; Ben Davidson; Gregg van de Putte; Hiep Phuc Dong; Iris Goldberg; Sivan Amir; Gunnar B Kristensen; Reuven Reich
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

4.  Matrix metalloproteinases (MMP), EMMPRIN (extracellular matrix metalloproteinase inducer) and mitogen-activated protein kinases (MAPK): co-expression in metastatic serous ovarian carcinoma.

Authors:  Ben Davidson; Vered Givant-Horwitz; Philip Lazarovici; Björn Risberg; Jahn M Nesland; Claes G Trope; Erik Schaefer; Reuven Reich
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

5.  Dissimilar invasive and metastatic behavior of vincristine and doxorubicin-resistant cell lines derived from a murine T cell lymphoid leukemia.

Authors:  Eloisi C Lopes; Glenda Ernst; Paula Aulicino; Silvia Vanzulli; Mariana García; Elida Alvarez; Silvia E Hajos
Journal:  Clin Exp Metastasis       Date:  2002       Impact factor: 5.150

6.  CD44 standard form expression is correlated with high-grade and advanced-stage ovarian carcinoma but not prognosis.

Authors:  Jing Zhang; Bin Chang; Jinsong Liu
Journal:  Hum Pathol       Date:  2013-05-07       Impact factor: 3.466

7.  High frequency of putative ovarian cancer stem cells with CD44/CK19 coexpression is associated with decreased progression-free intervals in patients with recurrent epithelial ovarian cancer.

Authors:  Ming Liu; Gil Mor; Huan Cheng; Xue Xiang; Pei Hui; Thomas Rutherford; Gang Yin; David L Rimm; Jennie Holmberg; Ayesha Alvero; Dan-Arin Silasi
Journal:  Reprod Sci       Date:  2012-11-20       Impact factor: 3.060

8.  Clinical relevance of CD44 surface expression in advanced stage serous epithelial ovarian cancer: a prospective study.

Authors:  Alaa A Elzarkaa; Bassma El Sabaa; Doaa Abdelkhalik; Hassan Mansour; Mahmoud Melis; Waleed Shaalan; Mohamed Farouk; Eduard Malik; Amr A Soliman
Journal:  J Cancer Res Clin Oncol       Date:  2016-01-13       Impact factor: 4.553

9.  Cell surface expression of hyaluronan on human ovarian cancer cells inversely correlates with their adhesion to peritoneal mesothelial cells.

Authors:  Yutaka Tamada; Hideyuki Takeuchi; Nao Suzuki; Daisuke Aoki; Tatsuro Irimura
Journal:  Tumour Biol       Date:  2012-03-06

10.  Coexpression of invasive markers (uPA, CD44) and multiple drug-resistance proteins (MDR1, MRP2) is correlated with epithelial ovarian cancer progression.

Authors:  H Chen; J Hao; L Wang; Y Li
Journal:  Br J Cancer       Date:  2009-07-14       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.